Comparison of the cost of antidepressants in a prostate cancer screening trial population
RATIU, ADELA (2011)
2011
Kansanterveystiede - Public Health
Terveystieteiden yksikkö - School of Health Sciences
This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited.
Hyväksymispäivämäärä
2011-07-31
Julkaisun pysyvä osoite on
https://urn.fi/urn:nbn:fi:uta-1-21765
https://urn.fi/urn:nbn:fi:uta-1-21765
Tiivistelmä
The aim of this study is to compare, in terms of the costs recorded in a comprehensive national register, the use of antidepressant drugs in both the control and screening arms of the Finnish trial.
A number of 76,223 reimbursement records for antidepressant drugs corresponding to 5,858 men in the control arm and 3,912 men in the screening arm were analysed for the period under study from 1996 to 2004.
We compared the control arm with the screening arm, the prostate-specific antigen (PSA) non-compliant group with the PSA compliant group and the group with the PSA<4 ng/mL with the PSA group≥4 ng/mL group in terms of the difference between the mean costs.
Our study showed little impact of the screening trial, of participation in the screening or of the concentration of prostate-specific antigen on the expenditure on antidepressant drugs. Further studies, based on supplementary information (i.e. quantity of antidepressant medicine) could contribute to a better assessment of the prostate cancer screening impact on mental health.
Asiasanat:cost, screening, prostate cancer, antidepressant drugs, PSA testing
A number of 76,223 reimbursement records for antidepressant drugs corresponding to 5,858 men in the control arm and 3,912 men in the screening arm were analysed for the period under study from 1996 to 2004.
We compared the control arm with the screening arm, the prostate-specific antigen (PSA) non-compliant group with the PSA compliant group and the group with the PSA<4 ng/mL with the PSA group≥4 ng/mL group in terms of the difference between the mean costs.
Our study showed little impact of the screening trial, of participation in the screening or of the concentration of prostate-specific antigen on the expenditure on antidepressant drugs. Further studies, based on supplementary information (i.e. quantity of antidepressant medicine) could contribute to a better assessment of the prostate cancer screening impact on mental health.
Asiasanat:cost, screening, prostate cancer, antidepressant drugs, PSA testing